UK markets closed

Vanda Pharmaceuticals Inc. (0LKB.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.20+0.14 (+2.77%)
At close: 03:57PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-37.91%
S&P500 52-week change 323.49%
52-week high 36.88
52-week low 33.30
50-day moving average 34.09
200-day moving average 34.82

Share statistics

Avg vol (3-month) 33.27k
Avg vol (10-day) 3952
Shares outstanding 552.45M
Implied shares outstanding 6N/A
Float 852.26M
% held by insiders 13.17%
% held by institutions 186.33%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -2.75%
Operating margin (ttm)-19.46%

Management effectiveness

Return on assets (ttm)-2.43%
Return on equity (ttm)-0.91%

Income statement

Revenue (ttm)177.6M
Revenue per share (ttm)3.09
Quarterly revenue growth (yoy)-24.10%
Gross profit (ttm)N/A
EBITDA -20.63M
Net income avi to common (ttm)-4.89M
Diluted EPS (ttm)0.32
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)394.14M
Total cash per share (mrq)6.77
Total debt (mrq)8.92M
Total debt/equity (mrq)1.64%
Current ratio (mrq)4.71
Book value per share (mrq)9.35

Cash flow statement

Operating cash flow (ttm)-11.43M
Levered free cash flow (ttm)-115.2M